Table 2. Baseline characteristics of patients without POAF from the included studies.
Study | Sample size
(n) |
Age
(mean ± SD) |
Male
n(%) |
Hypertension
n (%) |
Diabetes
n (%) |
Hyperlipidemia
n (%) |
Renal failure
n (%) |
CHF
n (%) |
COPD
n (%) |
Current Smoker
n (%) |
Follow up
duration (yrs) |
CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; POAF: post-operative atrial fibrillation. | |||||||||||
Almassi 2012[8] | 1552 | 61.6 ± 8.2 | 1552
(100%) |
1218
(85%) |
664
(43%) |
− (−) | − (−) | − (−) | 297
(19%) |
561
(36%) |
1 |
Almassi 2014[9] | 1547 | 62.4 ± 8.2 | 1547
(100%) |
1313
(84.9%) |
582
(37.6%) |
− (−) | − (−) | − (−) | 295
(19.1%) |
557
(36%) |
1 |
Batra 2019[10] | 6080 | 66 ± 6 | 4909
(81.7%) |
4128
(67.9%) |
1851
(30.4%) |
− (−) | 125
(2.1%) |
974
(16%) |
319
(5.2%) |
− (−) | 2.2 |
Bramer 2010[11] | 3976 | 64 ± 9.7 | 3081
(77.5%) |
1885
(47.4%) |
914
(23%) |
− (−) | − (−) | − (−) | 386
(9.7%) |
− (−) | 2.5 |
de Oliveira 2007[12] | − (−) | − (−) | − (−) | − (−) | − (−) | − (−) | − (−) | − (−) | − (−) | − (−) | Unspecified |
Fensgrud 2017[13] | 406 | 64.6±9.4 | 313
(77%) |
123
(30%) |
77
(19%) |
− (−) | − (−) | − (−) | − (−) | 251
(62%) |
15 |
Kalavrouziotis 2007[15] | 5300 | < 60 37.1%
60−69 32% 70−79 25.8% > 80 5.1% |
1404
(73.5%) |
3169
(59.8%) |
1738
(32.8%) |
− (−) | 254
(4.8%) |
663
(12.5%) |
652
(12.3%) |
− (−) | Unspecified |
Konstantino 2016[2] | 99 | 70±9 | 80
(81%) |
66
(67%) |
38
(39%) |
83
(84%) |
− (−) | − (−) | 12
(12%) |
38
(39%) |
8.5 |
Mankad 2019[16] | 200 | 64 | 198 | 184
(92%) |
84
(42.2%) |
− (−) | − (−) | 63
(31.5%) |
− (−) | − (−) | 5 |
Mariscalco 2009[17] | 6960 | 64.5 ± 9.5 | 5168
(74.2%) |
4109
(59%) |
1450
(20.8%) |
− (−) | − (−) | − (−) | − (−) | − (−) | 7.9 |
Saxena 2012[14] | 13950 | 64.02 ± 10.72 | − (−) | 10561
(75.7%) |
4580
(32.8%) |
11277
(80.3%) |
424
(3%) |
1874
(13.4%) |
1477
(10.6%) |
− (−) | 3.66 |